Canaery
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Canaery - overview
Established
2020
Location
-, FL, US
Primary Industry
Biotechnology
About
Canaery, based in Florida and founded in 2020, specializes in innovative scent-based products designed to enhance sensory experiences and emotional well-being for personal and home environments. Canaery is focused on creating scent solutions that explore the world of fragrances. Founded in 2020, the company has raised USD 1. 97 mn through a SEED funding round led by Breakout Ventures on March 2, 2022.
The current company valuation is USD 10. 27 mn. Gabriel Lavella serves as the CEO. Canaery specializes in scent-based products that unlock and explore fragrances.
Their offerings include innovative scent solutions for personal and home use that enhance sensory experiences. Targeting consumers who appreciate unique olfactory experiences, their products cater to various scenarios such as creating calming atmospheres or evoking nostalgia. Canaery markets primarily in North America and Europe, serving wellness enthusiasts, interior designers, and retailers. Canaery generates revenue through direct-to-consumer sales, allowing customers to purchase products online and through select high-end retail partners.
Their pricing reflects the premium quality of their scents, catering to different customer segments, including affordable luxury fragrances and exclusive limited editions. The firm emphasizes strong branding and customer loyalty, contributing to a sustained revenue stream. Canaery plans to leverage recent funding to support the development of new scent products and further expand into markets across North America and Europe. The funding raised in March 2022 will also facilitate marketing efforts to increase brand visibility.
Specific timelines for product launches and regional expansions are still in development.
Current Investors
Genesis, SOSV, IndieBio
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Diagnostic, Medical & Imaging Laboratories, Software
Website
www.canaery.com
Verticals
Artificial Intelligence, Research (Non-Medical)
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Canaery - employee data


Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.